Article Information
History
- July 24, 2020.
Article Versions
- Version 1 (June 15, 2020 - 22:01).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Naoki Iwanaga1,
- Laura Cooper2,
- Lijun Rong2,
- Brandon Beddingfield3,
- Jackelyn Crabtree4,
- Ralph A. Tripp4,
- Xuebin Qin3,5 and
- Jay K. Kolls1,6,*
- 1Departments of Pediatrics & Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA 70112, USA
- 2Departments of Microbiology and Immunology, College of Medicine University of Illinois at Chicago, Chicago, IL 60612 USA
- 3Departments of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA
- 4Departments of Infectious Diseases, Animal Health Research Center, University of Georgia, Athens, GA 30602 USA
- 5Tulane National Primate Research Center, Covington, LA 70433, USA
- ↵*Corresponding author; email: jkolls1{at}tulane.edu
Posted July 24, 2020.
Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2
